CDK4 and breast cancer: In vivo, RGT-419B sustains tumor growth inhibition (TGI) more effectively than abemaciclib in heterotransplanted ER + breast cancer models, underscoring its potential as a novel therapeutic option for patients with CDK4/6i-resistant or refractory ER + breast cancer (Xie et al., 2021).